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The authors studied the joint effect of blood pressure (BP)
and depression on the risk of major adverse cardiovascular
outcome in patients with existing cardiometabolic disease.
A cohort of 35,537 patients with coronary heart disease,
diabetes, or stroke underwent depression screening and BP
measurement recorded concurrently. The authors used
Cox’s proportional hazards to calculate risk of major
adverse cardiovascular event (MACE; myocardial infarc-
tion/heart failure/stroke or cardiovascular death) over
4 years associated with baseline BP and depression. A
total of 11% (3939) had experienced a MACE within
4 years. Patients with very high systolic BP (160–240 mm
Hg; hazard ratio, 1.28) and depression (hazard ratio, 1.22) at
baseline had significantly higher adjusted risk. Depression
had a significant interaction with systolic BP in risk
prediction (P=.03). Patients with a combination of high
systolic BP and depression at baseline had 83% higher
adjusted risk of MACE, as compared with patients with
reference systolic BP without depression. Patients with
cardiometabolic disease and comorbid depression may
benefit from closer monitoring of systolic BP. J Clin
Hypertens (Greenwich). 2016;18:1027–1035. ª 2016 The
Authors. The Journal of Clinical Hypertension Published by
Wiley Periodicals, Inc.
Blood pressure (BP) reduction is recommended for all
patients diagnosed with hypertension by various guide-
line bodies, especially for patients with cardiometabolic
disease (coronary heart disease [CHD], diabetes, and
previous stroke), as it is associated with a reduction in
the risk of future adverse cardiovascular (CV) out-
comes.1–4 However, a “J-shaped phenomenon” has also
been reported in epidemiological and interventional
studies for both systolic BP (SBP) and diastolic BP
(DBP), whereby BP lower than 130/80 mm Hg has been
associated with higher risk of adverse health outcomes
including fatal and nonfatal myocardial infarction (MI)
and stroke.5–8 The optimal level of BP control in
patients with existing cardiometabolic disease remains
an area of ongoing debate.9,10 Results from the recently
published Systolic Blood Pressure Intervention Trial
(SPRINT)11 suggest that patients with CHD may have a
lower risk of CV events with intensive SBP lowering
(<120 mm Hg).11
Patients with existing cardiometabolic diseases such
as CHD, diabetes, and stroke are two to three times
more likely to experience depressive symptoms than the
general population.12–14 Moreover, comorbid depres-
sion in these patients with cardiometabolic disease is
associated with higher risk of subsequent vascular
events.15–17 Depression screening, as a standalone
intervention, in these patient groups has not shown
any meaningful benefits in reducing CV events,18,19 and
it has been recommended that screening should be
followed by further evaluation by a professional qual-
ified in the diagnosis and management of depression.20
Depression treatment with models such as collaborative
care in cardiometabolic disease patient groups has been
found to be beneficial in reducing depressive symptoms
and improving treatment adherence but not useful in
reducing CV events.21,22
The relationship between depressive symptoms and
BP has been investigated in several cross-sectional
epidemiological studies.23–27 These studies have shown
that depression has a nonlinear relationship to SBP and
DBP, with greater depressive symptoms at both low and
high BP values.23–27 One longitudinal study concluded
that persistent depression leads to lowering of both
systolic and diastolic BP.28
The mediating mechanism for the observed higher risk
of CV events in patients with cardiometabolic disease and
comorbid depression remains unclear, with factors such
as autonomic dysfunction and chronic inflammation
proposed as contributors to a causal pathway.29 We
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hypothesized that patients with depression in car-
diometabolic disease with poor BP control may represent
a “high-risk” subtype, as the abovemechanisms have also
been associated with poor BP control.30,31
To date, the joint associations of depression and BP
with the risk of CV disease has not been studied. In this
study, we use data from a large cohort of primary care
patients with cardiometabolic disease (CHD/diabetes/
stroke), followed up for 4 years, to examine the
associations of depression and BP with the risk of
subsequent CV events. In doing so, we allow for both
nonlinearity of their effects and of interactions between
them.
METHODS
Study Design and Setting
The patient sample in this study was recruited from
two health boards in the West of Scotland that serve a
population of approximately 1.8 million. We received
approvals from the National Research Ethics Service
and National Services Scotland (NHS) Privacy
Advisory Committee and NHS Greater Glasgow and
Clyde Enhanced Services data group, which was the
authorized “guardian” of this data set. We retrospec-
tively analysed a large routinely collected data set,
which was completely anonymous with no patient
identifiers, therefore individual patient consent was
not obtained.
The local health boards oversaw a program of
incentivized depression screening in chronic disease as
part of a wider chronic disease management program of
Local Enhanced Services (LESs). Family practices in the
health boards studied were paid under the LES scheme
to carry out a comprehensive annual health assessment,
which included depression screening, for all patients
with one of the three common cardiometabolic condi-
tions: CHD, diabetes, and stroke. However, there were
no penalties for nonadherence. The nurse in the family
practice usually carried out the annual health assess-
ment and it lasted for approximately 1 hour. Patients
recognized as being “under treatment” for depression at
the time of their health assessment were exempt from
depression screening. Patients with a positive result on
depression screening were offered treatment as per
routine care for management of depressive symptoms
based on national guidelines.
Participants
The analysis described here was restricted to adults who
had a health assessment recorded for at least one of the
three conditions between January 4, 2008, to March 31,
2009, and were aged between 18 and 90 years, who
underwent depression screening. The “DepChron” data
set consisted of a total of 125,143 patients who were in
a family practice disease register with a diagnosis of at
least one of CHD, diabetes, or stroke in 2008–2009; all
of these patients underwent a comprehensive health
assessment as part of LES.32,33 Patients were labeled as
under treatment for depression and exempt from
depression screening if they were noted to be on
antidepressants based on their prescription record at
the time of depression screening.
Measurement of Clinical Variables
The depression subscale of the Hospital Anxiety and
Depression Scale (HADS-D)34 has a range of total score
from 0 to 21. A threshold of >7 was used to define the
presence of depressive symptoms, as endorsed by
national guidelines.35 The area-based Scottish Index of
Multiple Deprivations (SIMD) was used as a measure of
socioeconomic status, with patients categorized into
deciles of deprivation relative to the Scottish popula-
tion.36 Patients who were identified to have depressive
symptoms as a result of depression screening were
offered “routine care,” as recommended for manage-
ment of depressive symptoms in national guidelines.35 A
new antidepressant prescription for a period up to
6 months after screening was labeled as “new treat-
ment” for the screened patients. We also analyzed
antidepressant prescriptions after excluding amitripty-
line as it is often used in the management of chronic
pain in primary care. No reliable information was
available on the number of patients who were referred
for psychological therapies following their depression
screening.
SBP and DBP measurements and body mass index
(BMI) were recorded determined from height and
weight measurements. These BP measurements were
performed by the primary care practice nurse during
routine clinical assessments. As the data were collected
during routine clinical practice, information on methods
used for recording the BP (manual or digital; single
reading or multiple readings) was not available. A blood
sample was collected by the practice nurse at the time of
assessment, and the result for total cholesterol was
reported in mmol/L and glycated hemoglobin (only
available for patients with diabetes) was reported in
Diabetes Control and Complications Trial units.
We restricted the values for CV risk factors to clinically
plausible ranges based on both our clinical judgement
and the findings of general population studies.
SBP measurements were restricted to a range between
90 mm Hg and 240 mm Hg and DBP to a range
between 50 mm Hg and 130 mm Hg.37 Similarly,
BMI was restricted to a range between 15 mg/dL
and 55 mg/dL,38 total cholesterol between 2 mg/dL and
10 mg/dL,39 and glycated hemoglobin between 3%
and 18%.40 Observations in the data, which
were outside these ranges, were excluded from the
analysis.
Measurement of Outcome Variables
We used electronic data linkage methods to measure the
outcome variables for the patient cohort recruited in our
study for a follow-up duration of 4 years from April
2009 to March 2013. We electronically linked the
health records for patients in primary care registers with
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the records held by the Information Services Division
Scotland for any occurrence of hospitalization or
mortality during the follow-up period. We studied four
different clinical outcomes for the patients in our study
using the International Classification of Diseases–10th
Revision (ICD-10).41 The outcomes studied and their
respective ICD-10 codes are as follows:
1 Admission due to MI: I21
2 Admission due to stroke: I61-I64
3 Admission due to heart failure (HF): I50
4 Death due to CV causes: I00-I99.
Major adverse CV outcome (CV mortality or admis-
sion due to MI/stroke/HF) was used as the composite
outcome variable. Patients were censored if they expe-
rienced a composite CV outcome as described above or
if they died of reasons other than CV causes.
BP Measurement
There is no consensus among various guidelines pub-
lished internationally for optimal BP targets in patients
with existing cardiometabolic disease.1–4 We classified
BP into five different categories based on clinical
judgement to improve interpretability of results. SBP
was classified into five categories: very high (160–240
mm Hg), high (140–159 mm Hg), reference (130–139
mm Hg), tightly controlled (120–129 mm Hg), and low
(80–119 mm Hg). DBP was also classified into: very
high (100–130 mm Hg), high (90–99 mm Hg), reference
(85–89 mm Hg), tightly controlled (80–84 mm Hg), and
low (40–79 mm Hg). SBP and DBP were also added as
continuous variables in the regression models as
described below.
Statistical Analysis
We used time-to-event analysis to study the association
between three predictors: (1) SBP categories, (2) DBP
categories, and (3) presence of depressive symptoms,
and the risk of major adverse CV outcome in the study
population. Cox’s proportional hazards regression anal-
ysis was performed, unadjusted and adjusted for poten-
tial confounding factors, and the results are presented in
terms of hazard ratios (HRs) and 95% confidence
intervals (CIs). We performed multivariable analysis
adjusting for the following confounders: age (continu-
ous), sex (male and female), socioeconomic status
(deprived: SIMD deciles 1–5 vs affluent: SIMD deciles
6–10), initiation of antidepressants (yes/no), number of
cardiometabolic comorbidities (range 1–3, representing
a combination of one or more of the three car-
diometabolic diseases under investigations: CHD,
stroke, or diabetes), BMI (normal: 18.5–25 mg/dL,
underweight 15–18.5 mg/dL, overweight 25–30 mg/
dL, obese 30–50 mg/dL42), and total cholesterol levels
(not raised vs raised: >5 mmol/L4).
To understand the relationship between BP and
depressive symptoms in risk prediction of major adverse
CV outcome, if any, we carried out an analysis of
variance test to check for interaction between the BP
categories and presence of depressive symptoms. In the
event of a significant interaction, we also carried out a
subgroup analysis to further study the nature of inter-
action. In the subgroup analysis, the study sample was
divided on the basis of BP categories as described above.
In each subgroup, a Cox’s proportional hazards
regression analysis was performed to study the risk of
outcome with the presence of depressive symptoms at
baseline, adjusting for potential confounders. Analysis
was carried out using the R statistical software, version
3.0.2 (The R Project for Statistical Computing).
Sensitivity Analysis
We performed four different sensitivity analyses in the
following patients: those with diabetes, those with
affluent socioeconomic class, those with estimated
glomerular filtration rate results available at baseline,
and those with smoking and alcohol consumption
results available.
RESULTS
Patient Population and Clinical Outcomes
A total of 125,143 patients with at least one of the
following underwent a comprehensive health assess-
ment in 2008–2009: diabetes (62,275 patients), CHD
(62,990 patients), or previous stroke (26,060 patients).
A total of 10,670 (8.5%) patients were exempt from
depression screening as they were noted to be under
treatment for depression and excluded from analysis,
while the remaining 114,473 (91.5% of total sample
size) were eligible for depression screening. The uptake
of depression screening was low and HADS-D was
recorded in 35,537 (31.1% of those eligible) of those
undergoing the annual health assessment (Figure 1), and
it is the data from this subset that we focus on in this
paper. A total of 7080 of 35,537 patients had positive
HADS-D results (>7) at baseline. Electronic data linkage
between primary care disease registers and hospital
discharge and mortality records, based on Community
Health Index number was successful for 99.4% of
patients.
Among the patients who were screened (n=35,537),
12,485 (35.1%) had diabetes only, 11,716 (32.9%) had
CHD only, 3558 (10%) had previous stroke only, 7410
(20.8%) had two of these conditions, and 771 (2.1%)
had all of the three conditions. Table I compares the
demographic features, observed BP values, and the
absolute number of adverse CV outcomes for the
screened and unscreened population. In the study
population of patients with depression screening results
(n=35,537), 11% (3939) experienced at least one major
adverse cardiovascular event (MACE) within 4 years. In
the study population, the observed mean SBP at baseline
was 133 mm Hg in the reference SBP group (130–139
mm Hg), 123 mm Hg in the tightly controlled SBP
group (120–129 mm Hg), 109 mm Hg in the low SBP
group (80–119 mm Hg), 145 mm Hg in the high SBP
group (140–159 mm Hg), and 170 mm Hg in the very
high SBP group (160–240 mm Hg).
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BP, Depressive Symptoms, and Risk of a MACE at
4 Years
In the adjusted multivariable analyses for SBP cate-
gories, patients with very high SBP (160–240 mm Hg)
and low SBP (80–119 mm Hg) at baseline had a
significantly higher risk of a MACE at 4 years compared
with patients with reference SBP (130–139 mm Hg) at
baseline (Table II). There was no statistical difference in
the risk between patients with reference SBP, tightly
controlled SBP (120–129 mm Hg), and high SBP (140–
159 mm Hg) at baseline. The adjusted risk was 15%
higher for patients with low SBP and 28% higher for
patients with very high SBP compared with patients
with reference SBP at baseline. The presence of depres-
sive symptoms (HADS-D >7) at baseline was associated
with a 22% higher adjusted risk of a major CV event
compared with those without depressive symptoms
(Table II). Figure 2 shows that patients with high SBP
had a significantly higher cumulative incidence rate
compared with patients in the other SBP categories;
similarly, patients with depressive symptoms had
a higher cumulative incidence than those without
depression.
In the adjusted analysis for DBP categories, none of
the DBP categories at baseline had any statistically
significant difference in the risk prediction of MACE,
compared with the reference (Table II). The results were
adjusted for age, sex, socioeconomic status, number of
CV comorbidities, BMI, and total cholesterol values at
baseline and initiation of antidepressants within
6 months of depression screening. Interestingly, initia-
tion of antidepressants after depression screening did
not have any significant impact on the risk of MACE
(HR, 0.84; 95% CI, 0.68–1.04; P=.11). SBP as a
continuous variable was found to have a significant
nonlinear relationship with risk prediction of a MACE
while DBP was not a significant predictor as a contin-
uous variable in the multivariable analysis (results not
shown). We also repeated the analysis by adjusting for
different disease categories and combinations among the
three cardiometabolic diseases, and there was no
difference in the results (not shown).
Interaction Between SBP and Depressive Symptoms
in Risk Prediction of Major CV Event at 4 Years
In the risk prediction of major CV event, the interaction
between SBP categories and presence of depressive
symptoms was statistically significant (P=.03). Patients
with low SBP (80–119 mm Hg) only, with very high SBP
(160–240 mm Hg) only, and depressive symptoms only
at baseline had 10%, 19%, and 17% adjusted higher
risks of a major CV event, respectively, compared with
those without extremes of SBP and no depressive
symptoms (Figure 3). In comparison, patients with both
low SBP and depressive symptoms at baseline had a
36% (95% CI, 15%–62%) higher risk while patients
with both very high SBP and depressive symptoms had
the highest increased risk of 83% (95% CI, 46%–
130%) compared with those in the reference SBP group
without depressive symptoms.
In the multivariable subgroup analysis of five SBP
categories, a nonlinear trend was observed in the
association between presence of depressive symptoms
and risk prediction of a major CV event at 4 years
(Table III). There was no evidence of an association
between the presence of depressive symptoms and
adjusted risk of major adverse event for the subgroup
of patients with reference SBP (130–139 mm Hg) at
baseline. Presence of depressive symptoms was associ-
ated with significantly higher risk of a major CV adverse
FIGURE 1. Study sample size and recruitment.33 CHD indicates coronary heart disease; HADS, Hospital Anxiety and Depression Score.
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event for patients in all other baseline SBP categories.
Patients with very high SBP and concurrent depressive
symptoms had the highest absolute event rate of 17.7%;
moreover, the change in the adjusted risk with addition
of depressive symptoms was highest for the subgroup of
patients with very high SBP at 55% (Table III).
Sensitivity Analysis
In all four sensitivity analyses, the subgroup of patients
with very high SBP and prevalent depressive symptoms
were observed to have the highest absolute event rate of
CV outcomes. In addition, in SBP subgroup analysis,
presence of depressive symptoms (against no depressive
symptoms) was observed to have the highest adjusted
effects size for MACE in the very high SBP subgroup for
all four sensitivity analyses. These results are presented
in detail in the supplementary information.
DISCUSSION
Summary of Findings
Patients with existing cardiometabolic disease and those
with very high and low SBP at baseline were observed to
have a significantly higher adjusted risk of a MACE than
those with SBP in the reference range. Presence of
depressive symptoms at baseline was also associated
with a significantly higher risk of a MACE, while DBP
was not a significant predictor in the multivariable
analysis in either pooled or subgroup analysis. Presence
of depressive symptoms compounded the risk of a
MACE in patients with very high SBP.
Strengths and Limitations
This study has a number of key strengths, in that the
data came from a large, community-based sample
reflecting real-life clinical practice, and electronic data
TABLE I. Comparison of the Depression Screened
and Unscreened Patient Groups in Existing
Cardiometabolic Disease
Depression
Screened
(n=35,537)
Depression
Unscreened
(n=78,936) P Value
Age, mean (SD), y 69.0 (11.9) 67.0 (14.3) <.001
White ethnicity, No. (%) 30,693 (92.4) 53,343 (90.3) <.001
Male sex, No. (%) 20,658 (58.2) 42,727 (54.2) <.001
Deprived socioeconomic
status SIMD deciles ≤5,
No. (%)
22,726 (65.3) 51,686 (67.4) <.001
Number of cardiometabolic conditions, No. (%)
One 27,356 (77.0) 65,417 (82.9) <.001
Two 7410 (20.9) 12,265 (15.5)
Three 771 (2.2) 1254 (1.6)
Antidepressant
initiation, No. (%)
1268 (3.5) 4989 (6.3) <.001
Systolic blood pressure, No. (%)
130–139 mm Hg
(reference)
8389 (23.6) 13,315 (16.8) <.001
120–129 mm Hg
(tightly controlled)
6864 (19.3) 10,818 (13.7)
80–119 mm Hg (low) 5711 (16.0) 9258 (11.7)
140–159 mm Hg (high) 8624 (24.2) 15,969 (20.2)
160–240 mm Hg
(very high)
2514 (7.0) 5778 (7.3)
Not available 3435 (9.6) 23,802 (30.1)
Diastolic blood pressure, No. (%)
85–89 mm Hg
(reference)
1909 (5.3) 4219 (5.3) <.001
80–84 mm Hg (tightly
controlled)
7070 (19.8) 13,088 (16.5)
40–79 mm Hg (low) 20,585 (57.9) 31,724 (40.1)
90–99 mm Hg (high) 1981 (5.5) 4450 (5.6)
100–130 mm Hg
(very high)
562 (1.5) 1649 (2.0)
Not available 3430 (9.6) 23,806 (30.1)
Major adverse
cardiovascular outcome
(cardiovascular death or
admission due to
MI/stroke/heart failure),
No. (%)
3939 (11) 10,990 (13.9) <.001
Abbreviations: MI, myocardial infarction; SD, standard deviation;
SIMD, Scottish Index of Multiple Deprivation.
TABLE II. SBP, DBP, and Presence of Depressive
Symptoms (HADS-D >7) at Baseline and Risk
Prediction of Major Adverse Cardiovascular Event
(Cardiovascular Death or Admission Due to MI/
Stroke/HF) in 35,537 Patients With Previous Stroke,
Coronary Heart Disease, or Diabetes at 4 Years of
Follow-Up
Predictors at
Baseline
Major Adverse Cardiovascular Event
Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)a
SBP, mm Hg
80–119 1.15 (1.04–1.27) 1.15 (1.03–1.29)
120–129 0.99 (0.90–1.09) 1.00 (0.90–1.12)
130–139 1 1
140–159 1.10 (1.00–1.20) 1.07 (0.96–1.18)
160–240 1.43 (1.26–1.61) 1.28 (1.11–1.49)
DBP, mm Hg
40–79 1.24 (1.07–1.44) 0.94 (0.78–1.12)
80–84 1.05 (0.89–1.23) 0.93 (0.77–1.12)
85–89 1 1
90–99 0.83 (0.67–1.02) 0.90 (0.71–1.14)
100–130 1.03 (0.77–1.39) 1.15 (0.82–1.62)
HADS-D >7
Reference=HADS-D ≤7
1.23 (1.14–1.32) 1.22 (1.11–1.33)
Abbreviations: CI, confidence interval; DBP, diastolic blood pressure;
HADS-D, Hospital Anxiety and Depression Score-depression sub-
scale; HF, heart failure; HR, hazard ratio; MI, myocardial infarction;
SBP, systolic blood pressure.
aAdjusted for confounders including body mass index, total choles-
terol, age, sex, socioeconomic status, number of comorbid condi-
tions, and initiation of antidepressants. Significant results are
indicated in bold.
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linkage enabled successful follow-up for the majority of
patients in the cohort. There are several limitations.
Only a minority of the patients in the sample had
depression screening recorded despite incentivization.
Consequently, there may be important differences
between patients with known depression status and
those whose depression status was unknown that were
not recorded in our data. In addition, we did not have
information on depression score or CV events for the
cohort of patients noted to be “under treatment” for
depression at the time of depression screening, which is
an important limitation.
The observed association between low SBP at baseline
and higher risk of major adverse CV outcomes could be
caused by reverse causality, where patients with low
SBP could be those with the most severe form of disease.
There was no available information on disease severity
for the study participants, which is an important
limitation. Morevoer, we had insufficient information
on biobehavioral factors such as smoking status, alcohol
consumption, and levels of physical activity and hence
we were unable to adjust the main results for these
factors. Biobehavioral factors are likely to influence the
prevalence of depressive symptoms in cardiometabolic
disease patients and, in turn, may affect the ability to
make positive health-related behavior changes and
influence outcomes.43–45 Information on cardiac-related
medications was not available for these patients. How-
ever, these patients had existing cardiometabolic disease
and were attending their primary care providers for
annual health assessment. Hence, the majority of them
were likely to be taking at least one medication that
could lower BP. In addition, we had information only
on initiation of antidepressants but did not have
information either on duration of antidepressants or
on the different class of antidepressants chosen.
FIGURE 2. Kaplan-Meier plots comparing unadjusted cumulative event rates for major adverse cardiovascular outcome based on systolic
blood pressure (SBP) values and presence of depressive symptoms at baseline in patients with existing cardiometabolic disease. A total of
35,537 patients with previous stroke, coronary heart disease, or diabetes. Major adverse cardiovascular event=cardiovascular death or
admission due to myocardial infarction/stroke/heart failure. Reference SBP=130–139 mm Hg, tightly controlled SBP=120–129 mm Hg, low
SBP=80–119 mm Hg, high SBP=140–159 mm Hg, very high SBP=160–240 mm Hg. Depressive symptoms (defined as Hospital Anxiety and
Depression Scale-depression subscale >7) at baseline.
FIGURE 3. Forest plot showing interaction between depressive
symptoms and extremes of systolic blood pressure (SBP) at
baseline with the risk of major adverse cardiovascular event at
4 years in patients with existing cardiometabolic disease. A total of
35,537 patients with previous stroke, coronary heart disease, or
diabetes. A forest plot for comparing cumulative hazard for major
adverse cardiovascular event (cardiovascular death or admission
due to myocardial infarction/stroke/heart failure) for patients with
very high (160–240 mm Hg) and low (80–119 mm Hg) SBP and
depressive symptoms (defined as Hospital Anxiety and Depression
Scale-depression subscale >7) at baseline.
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Moreover, there are other adverse clinical outcomes
of significance in this group of patients such as renal
failure, angina pectoris, and retinopathy.8,46 We did not
have information available for these outcomes in our
data. Finally, the overall accuracy of depression screen-
ing in our study was reliant on HADS-D, which is a self-
reported measure and has accuracy-related drawbacks
when used for assessing depressive symptoms in patients
with cardiometabolic disease in a primary care
setting.18,47
Comparison With Existing Literature
The association between presence of depressive symp-
toms and higher risk of adverse clinical outcomes in
patients with preexisting cardiometabolic disease has
been previously reported in the literature.15–17 SBP at
baseline was found to have a nonlinear relationship in
our study with the risk prediction of a MACE, which
has also been reported in various other studies.5,6,8 Our
study findings are contrary to the results observed in the
SPRINT trial, but there are important differences such
as the study design and setting. In addition, the SPRINT
trial excluded patients with diabetes and previous
stroke, who were included in our study.11 With regards
to DBP, our study found that DBP at baseline was not a
significant predictor of adverse CV outcomes, and there
are studies that have reported similar findings of better
predictive power of SBP over DBP in predicting CV
outcomes.48,49
This is the first study, to our knowledge, to investigate
the interacting relationship between depressive symp-
toms and BP in risk prediction of adverse clinical
outcomes in patients with preexisting cardiometabolic
disease.
CLINICAL IMPLICATIONS
Firstly, there may be potential benefits of depression
screening for patients with cardiometabolic disease who
have extremes of SBP. Secondly, cardiometabolic dis-
ease patients who are diagnosed with comorbid depres-
sive symptoms may benefit from closer monitoring of
their SBP for secondary prevention of CV events.
Further research is needed in this area before making
any clinical recommendations.
CONCLUSIONS
SBP and depressive symptoms at baseline were indepen-
dent predictors of a MACE at 4 years in patients with
existing cardiometabolic disease, while DBP at baseline
did not have a significant effect. Presence of depressive
symptoms compounded the risk of a MACE in SBP
categories both higher and lower than the reference SBP,
especially in patients with very high SBP. There may be
potential benefits from closer monitoring (over and
above routine care) of BP in patients with car-
diometabolic disease and comorbid depression. Further
research is needed to understand the relationship
between extremes of BP and depressive symptoms in
patients with existing cardiometabolic disease and the
underpinning biological mechanisms.
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